Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

RCT (n=1,930) found addition of S-1 therapy (oral fluoropyrimidine) to endocrine therapy improved disease free survival (DFS) vs endocrine therapy alone (after median 52.2 months,,101 [11%] vs. 55 [16%], respectively, had invasive DFS events; HR 0.63, 95% CI 0.49–0.81, p=0.0003).

Source:

The Lancet Oncology